A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.03.008
Abstract: Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We… read more here.
Keywords: hma failure; smoothened inhibitor; glasdegib; response ... See more keywords
How I treat MDS after hypomethylating agent failure.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-03-785915
Abstract: Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient. Prediction of response… read more here.
Keywords: hypomethylating agent; hma failure; treat mds; mds hypomethylating ... See more keywords
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018015529
Abstract: Hypomethylating agent (HMA) failure in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) carries a poor prognosis with limited treatment options. Although intensive, remission induction chemotherapy is often used subsequently, in particular to bridge to… read more here.
Keywords: hypomethylating agent; hma failure; myeloid leukemia; acute myeloid ... See more keywords